The competition for weight-loss pills between Eli Lilly and Novo Nordisk is anticipated to contribute to the growing market for obesity drugs, estimated to reach $200 billion. This showdown in the weight-loss pills market is making headlines as the two pharmaceutical giants vie for a larger share of this lucrative industry.